Mediators of chronic obstructive pulmonary disease

被引:455
|
作者
Barnes, PJ [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, London SW3 6LY, England
关键词
D O I
10.1124/pr.56.4.2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic obstructive pulmonary disease (COPD) is a major and increasing global health problem that is now a leading cause of death. COPD is associated with a chronic inflammatory response, predominantly in small airways and lung parenchyma, which is characterized by increased numbers of macrophages, neutrophils, and T lymphocytes. The inflammatory mediators involved in COPD have not been clearly defined, in contrast to asthma, but it is now apparent that many lipid mediators, inflammatory peptides, reactive oxygen and nitrogen species, chemokines, cytokines, and growth factors are involved in orchestrating the complex inflammatory process that results in small airway fibrosis and alveolar destruction. Many proteases are also involved in the inflammatory process and are responsible for the destruction of elastin fibers in the lung parenchyma, which is the hallmark of emphysema. The identification of inflammatory mediators and understanding their interactions is important for the development of anti-inflammatory treatments for this important disease.
引用
收藏
页码:515 / 548
页数:34
相关论文
共 50 条
  • [1] Pathogenesis of chronic obstructive pulmonary disease -: the role of cells and mediators in chronic inflammation
    Krol, Malgorzata
    Kraus-Filarska, Maria
    Obojski, Andrzej
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2007, 16 (02): : 277 - 285
  • [2] Inflammatory lipid mediators in Chronic Obstructive Pulmonary Disease: Association with the disease severity
    Hedhli, Abir
    Jelassi, Warda
    Euchi, Khadija
    Mjid, Meriem
    Ouahchi, Yacine
    Cheikhrouhou, Sana
    Toujani, Sonia
    Dhahri, Besma
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [3] Phenotypic Profiling of Immune Cells and Their Mediators in Chronic Obstructive Pulmonary Disease
    Sampath, Meghashree
    Bade, Geetanjali
    Guleria, Randeep
    Mohan, Anant
    Sen, Sudip
    Dey, Devanjan
    Talwar, Anjana
    BIOMEDICINES, 2023, 11 (08)
  • [4] Profiling of Sputum Inflammatory Mediators in Asthma and Chronic Obstructive Pulmonary Disease
    Bafadhel, M.
    McCormick, M.
    Saha, S.
    McKenna, S.
    Shelley, M.
    Hargadon, B.
    Mistry, V.
    Reid, C.
    Parker, D.
    Dodson, P.
    Jenkins, M.
    Lloyd, A.
    Rugman, P.
    Newbold, Paul
    Brightling, C. E.
    RESPIRATION, 2012, 83 (01) : 36 - 44
  • [5] LIPID MEDIATORS IN CYSTIC-FIBROSIS AND CHRONIC OBSTRUCTIVE PULMONARY-DISEASE
    ZAKRZEWSKI, JT
    BARNES, NC
    COSTELLO, JF
    PIPER, PJ
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1987, 136 (03): : 779 - 782
  • [6] Vascular Risk in Chronic Obstructive Pulmonary Disease: Role of Inflammation and Other Mediators
    Man, S. F. Paul
    Van Eeden, Stephan
    Sin, Don D.
    CANADIAN JOURNAL OF CARDIOLOGY, 2012, 28 (06) : 653 - 661
  • [7] Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease
    Pesci, A
    Balbi, B
    Majori, M
    Cacciani, G
    Bertacco, S
    Alciato, P
    Donner, CF
    EUROPEAN RESPIRATORY JOURNAL, 1998, 12 (02) : 380 - 386
  • [8] Interrelationship between serum and sputum inflammatory mediators in chronic obstructive pulmonary disease
    Bizeto, L.
    Mazzolini, A. B.
    Ribeiro, M.
    Stelmach, R.
    Cukier, A.
    Nunes, M. P. T.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2008, 41 (03) : 193 - 198
  • [9] Asthma and chronic obstructive pulmonary disease overlap: asthmatic chronic obstructive pulmonary disease or chronic obstructive asthma?
    Slats, Annelies
    Taube, Christian
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2016, 10 (01) : 57 - 71
  • [10] Chronic Obstructive Pulmonary Disease 3 Controversies in treatment of chronic obstructive pulmonary disease
    Rabe, Klaus F.
    Wedzicha, Jadwiga A.
    LANCET, 2011, 378 (9795): : 1038 - 1047